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Abstract
Hepatitis E virus (HEV), the causative agent of hepatitis E, is primarily transmitted via the fecal-
oral route through contaminated water supplies, although many sporadic cases of hepatitis E are
transmitted zoonotically via direct contact with infected animals or consumption of contaminated
animal meats. Genotypes 3 and 4 HEV are zoonotic and infect humans and other animal species,
whereas genotypes 1 and 2 HEV are restricted to humans. There exists a single serotype of HEV,
although the cross-protective ability among the animal HEV strains is unknown. Thus, in this
study we expressed and characterized N-terminal truncated ORF2 capsid antigens derived from
swine, rat, and avian HEV strains and evaluated their cross-protective ability in a pig challenge
model. Thirty, specific-pathogen-free, pigs were divided into 5 groups of 6 pigs each, and each
group of pigs were vaccinated with 200 µg of swine HEV, rat HEV, or avian HEV ORF2 antigen
or PBS buffer (2 groups) as positive and negative control groups. After a booster dose
immunization at 2 weeks post-vaccination, the vaccinated animals all seroconverted to IgG anti-
HEV. At 4 weeks post-vaccination, the animals were intravenously challenged with a genotype 3
mammalian HEV, and necropsied at 4 weeks post-challenge. Viremia, fecal virus shedding, and
liver histological lesions were compared to assess the protective and cross-protective abilities of
these antigens against HEV challenge in pigs. The results indicated that pigs vaccinated with
truncated recombinant capsid antigens derived from three animal strains of HEV induced a strong
IgG anti-HEV response in vaccinated pigs, but these antigens confer only partial cross-protection
against a genotype 3 mammalian HEV. The results have important implications for the efficacy of
current vaccines and for future vaccine development, especially against the novel zoonotic animal
strains of HEV.
© 2012 Elsevier Ltd. All rights reserved.
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Introduction
Hepatitis E virus (HEV), the causative agent of acute hepatitis E in humans, is an important
pathogen worldwide [1–4]. The mortality rate can reach up to 28% in HEV-infected
pregnant women, although it is less than 1% in the general populations [5]. Large outbreaks
of acute hepatitis E due to contaminated water sources occur in countries where modern
sanitation practices are not commonly implemented [3, 6]. While less common, zoonotic
transmissions leading to sporadic or cluster cases of acute hepatitis E are a growing concern
in both industrialized and developing countries [2]. Thus far, at least four recognized and
two putative genotypes of mammalian HEV have been identified worldwide. The genotypes
1 and 2 HEV infect only humans, while genotypes 3 and 4 HEV have an expanded host
range and are zoonotic [2–4]. The putative genotypes 5 and 6 were recently identified from
wild boars in Japan [10] and rats in Germany [21], respectively.
Meng et al (1997) identified the first animal strain of HEV in pigs designated as swine HEV,
while another animal strain of HEV, avian HEV, was isolated from chickens in 2001 [7, 8].
HEV infection in pigs appears to be asymptomatic [7]. All swine HEV strains identified
worldwide thus far belong to either genotype 3 or 4 [2, 3, 9] except for a putative new
genotype recently isolated from a wild boar in Japan [10]. Genotypes 3 and 4 HEV are able
to infect across species barriers [2–4, 11]. Additionally, a variant strain of genotype 3 HEV
isolated from rabbits was capable of infecting pigs [12]. Confirmed zoonotic human
infections arise primarily from consumption of contaminated pig liver, pork products, and
deer meats [13, 14] as these products contain infectious HEV [15].
Avian HEV is enzootic within chicken flocks and is identified as the cause of hepatitis-
splenomegaly syndrome (HS syndrome) [16]. Thus far at least three genotypes of avian
HEV have been identified from chickens worldwide including the United States, Australia,
Spain, and China [17–20]. Avian HEV only shares 50–60% nucleotide sequence identity
with swine or human HEV strains and likely belongs to a separate genus [8, 17, 18]. Besides
pigs, humans, and chickens, HEV has also been genetically identified from rats [21, 22],
mongoose [3], deer [14, 23], rabbits [24, 25], and even fish [26]. All mammalian HEV
genotypes identified thus far belong to a single serotype.
Recombinant ORF2 capsid proteins of HEV are capable of inducing neutralizing antibodies
when used as candidate vaccines in humans [27, 28], non-human primates [29], and
chickens [30]. These candidate vaccines contain immunogenic epitopes toward the C-
terminus of the 660 amino acid capsid protein [31]. When the 111 N-terminal amino acids
are absent, the truncated capsid protein forms virus-like particles (VLPs) [32] which
enhance vaccine efficacy [32, 33]. HEV capsid antigens are capable of cross-reacting with
antibodies from heterologous HEV strains [12, 34, 35] while convalescent sera from animals
infected with any of the four recognized HEV genotypes were capable of neutralizing
genotype 1 HEV in vitro [31]. The objective of this study was to determine if the
recombinant capsid antigens derived from swine, rat, and avian HEV strains can induce
cross-protection against a genotype 3 HEV challenge in a pig model.
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Materials and Methods
Expression and purification of truncated recombinant capsid proteins derived from swine,
rat, and avian HEV strains
The N-terminal truncated capsid proteins from swine, rat, and avian HEVs were expressed
in a bacterial expression system to generate the immunogenic ORF2 capsid proteins lacking
the 111 N-terminal amino acid residues [32, 36]. Briefly, the truncated ORF2 genes were
amplified from respective plasmids containing avian, genotype 3 swine, and rat HEV ORF2
genes with strain-specific primers (Table 1). Each amplified PCR product was gel-purified,
digested with restriction enzymes, and subsequently cloned into the pRSET-A bacterial
expression vector (Invitrogen). The authenticity of each ORF2 gene insert was verified by
sequencing. Each recombinant pRSET-A plasmid was transformed into BL21(DE3)pLysS
(Novagen) E. coli cells and then grown in an auto-inducing expression system using
Overnight Express Instant TB Medium (Novagen) essentially as described [12]. To facilitate
the purification of the resulting recombinant capsid proteins, six histidine residues were
incorporated into the proteins.
To purify the recombinant capsid proteins, bacterial cell pellets were lysed with BugBuster
Protein Extraction Reagent (Novagen) mixed with 6M urea as a denaturant for the otherwise
insoluble protein. Histidine-tagged proteins were extracted from the supernatant of cell
lysates using HisPur nickel spin columns. Each protein solution underwent sequential
dialysis steps against decreasing concentrations of urea using Slide-A-Lyzer dialysis
cassettes (Thermo Scientific) with the final urea concentrations of 2M in Tris-HCL buffer.
Each recombinant capsid protein was confirmed by Western blot using IRDye800
conjugated with antibody against poly-histidine residues, and visualized with an Odyssey
Imager (LI-COR Biosciences) at 800nm. Additionally, Western blot was also performed
using a hyperimmune antiserum from a pig immunized with a purified recombinant capsid
antigen of a genotype 1 HEV as the primary detecting antibody [7]. The secondary antibody
was IRDye800 conjugated with anti-swine antibody as previously described [12]. Each
protein was diluted with the final elution buffer to a concentration of 200 µg/ml and stored at
−80°C.
Challenge HEV virus stocks
The genotype 3 HEV (Meng strain) virus stock with a 104.5 50% pig infectious dose (PID50)
was used as the challenge virus. The generation and titration of the infectious virus stock
was reported previously [37, 38].
Vaccination and challenge experimental design
Thirty, 5-week-old, specific-pathogen-free (SPF), pigs that were negative for IgG anti-HEV
were separated into 5 groups of 6 pigs each and housed in a BSL-2 facility. Pigs in each
group were vaccinated intramuscularly with 1 ml of PBS (later challenged with PBS as
negative control), PBS (later challenged with HEV as positive control), swine HEV capsid
antigen, rat HEV capsid antigen, or avian HEV capsid antigen. At two weeks post-
vaccination (wpv), a booster dose of each antigen was administered to each pig. Each ml of
vaccine contained approximately 200µg of respective antigen and was administered equally
(0.5 ml) to muscles on each side of the neck. At 4 wpv when the vaccinated pigs all
developed a high titer of IgG anti-HEV, all pigs with the exception of the negative control
group were intravenously challenged with 1 ml of the prototype genotype 3 HEV (Meng
strain) containing 104.5 PID50 infectious virus. The negative control pigs were challenged
with PBS buffer. All pigs were necropsied at 4 weeks post-challenge (wpc) at which time
the microscopic lesions in the liver peak [39].
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Sample collection
Serum samples and fecal swab materials were collected prior to vaccination and weekly
thereafter from each pig. Following vaccination, the weekly serum samples were tested for
IgG anti-HEV by an ELISA [7]. After challenge, the sera and 10% suspension of fecal
samples were tested weekly for the presence of HEV RNA by a nested RT-PCR. Liver, bile,
and small intestinal contents were collected at necropsy. Bile and 10% suspension of small
intestinal contents were tested for HEV RNA while the liver samples were evaluated for
histological hepatic lesion by a pathologist using a scoring system previously described [39].
RT-PCR to detect HEV RNA
Serum and fecal samples were tested by a genotype 3 HEV-specific nested RT-PCR as
described previously [37] except that the strain-specific primers target the ORF1 gene.
Briefly, total RNAs were extracted from 100 µl of 10% fecal suspension or serum samples
using TriZol reagents (Life Technologies) and resuspended in 30 µl of sterile water. Reverse
transcription reactions were performed at 42°C for 1 hr with 1 µl (10 µM) of the external
reverse primer HEVORF1-REV1, 1 µl (200 units/µl) of Superscript II reverse transcriptase
(Life Technologies), 1 µl of 0.1M dithiothreitol, 4 µl of 5× RT buffer, 0.5 µl (40 units/µl) of
RNasin ribonuclease inhibitor (Promega), and 1 µl of 10 mM deoxynucleoside
triphosphates. For the first round PCR, forward primer HEVORF1-FWD1 and reverse
primer HEVORF1-REV1 (Table 1) were used to amplify a 471 bp product. For the second
round nested PCR, forward primer HEVORF1-FWD2 and reverse primer HEVORF1-REV2
(Table 1) were utilized to amplify a 277 bp fragment using 5 µl of the first round PCR
product as the template and AmpliTaq Gold DNA polymerase (Applied Biosystems). The
cycling parameters included an initial denaturation/polymerase activation step at 95°C for 9
min, followed by 39 cycles of denaturation for 1 min at 94°C, annealing for 1 min at 52°C,
extension for 1 min at 72°C, and a final extension step at 72°C for 7min. The resulting PCR
products were analyzed via electrophoresis on a 1% agarose gel.
Enzyme-linked immunosorbent assay (ELISA) to detect IgG anti-HEV
Pig serum samples were tested by an ELISA as previously described [7, 37, 40] except that
the respective homologous antigen derived from swine, avian and rat HEVs was used in this
study. The ELISA cutoff was set at 3 standard deviations above the mean OD values of the
pre-vaccinated serum samples. All sera were tested in duplicate at a 1:100 dilution.
Statistical analyses
Histopathologic lesions were recorded as lesion scores (Table 2). The means of lesion scores
were compared by an unpaired t-test (Excel, Microsoft Inc.). A P-value below 0.05 was
considered significant.
RESULTS
Characterization of the truncated recombinant capsid antigens of swine, rat, and avian
HEV expressed in E. Coli
The truncated ORF2 proteins derived from swine, avian and rat HEV were each expressed
as insoluble inclusion bodies with an approximate predicted size of 58 kDa [41]. Following
nickel affinity chromatography purification, the his-tag fused to each protein was properly
identified on each of the recombinant fusion proteins using Western blot with IRDy800 (LI-
COR Biosciences) conjugated antibodies to poly-histidine tags (Fig. 1A). Further Western
blot analyses using anti-HEV ORF2 hyperimmune swine antiserum raised against a
genotype 1 human HEV confirmed the expression of swine, rat, and avian ORF2 proteins
(Fig. 1B). The antiserum raised against the genotype 1 human HEV cross-reacted to the
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truncated recombinant capsid antigens from genotype 3 swine HEV, avian HEV and rat
HEV (Fig. 1B), further confirming the existence of a single HEV serotype.
The truncated recombinant capsid antigens derived from swine, rat, or avian HEV induced
strong IgG anti-HEV antibody responses in vaccinated pigs
Pigs vaccinated intramuscularly with swine, rat, or avian HEV ORF2 capsid antigens all
developed strong IgG anti-HEV antibody responses as detected with the respective antigen-
specific ELISA (Fig 2B, 2C, 2D). There was no detectable difference in the level or pattern
of antibody responses among the vaccinated groups, indicating that the capsid antigens
derived from different animal HEV sources are capable of inducing antibody production in
pigs. After a booster dose at two weeks after the initial vaccination, all pigs in each group
seroconverted to IgG anti-HEV. The control pigs that were vaccinated with PBS were
seronegative (Fig 2A).
Hepatic histological lesion scores at 4 weeks post-challenge (wpc)
Sections of liver samples from each pig were collected at necropsy at 4 wpc and processed
for routine histological examination for the presence or absence of lymphoplasmacytic
hepatitis (Table 2) by a pathologist as described previously [39]. Only mild
lymphoplasmacytic hepatitis was observed (Table 2), which is consistent with previous
studies [39], as genotype 3 HEV infection is generally subclinical in pigs [7]. In general, the
pigs vaccinated with avian, swine or rat HEV antigens all had lower average mean
histological scores when compared to the unvaccinated and challenged pigs (Table 2).
Interestingly, the group with the lowest average hepatic lesion score was vaccinated with the
avian HEV ORF2 antigen.
Detection of HEV RNA in serum and feces with RT-PCR
After challenge, the detection of HEV RNA was performed using a nested RT-PCR with
primers that target the ORF1 gene regions. Positive and negative control sera or fecal
suspension of a genotype 3 HEV were included in all steps of the RNA extraction, reverse
transcription and nested PCR processes to ensure proper performance of the RT-PCR. HEV
viremia was not detected in any of the challenged pigs, which is consistent with the nature of
genotype 3 HEV infection in pigs (Table 3). All 6 unvaccinated pigs shed virus in feces after
challenge, and the virus shedding lasted 1–2 weeks (Table 3). In contrast, pigs vaccinated
with swine HEV or avian HEV had only 3 pigs within each group that shed virus in feces,
although the pigs vaccinated with rat HEV antigen all had fecal virus shedding. At necropsy,
HEV RNA was not detected in the bile or small intestinal contents of any pig. As expected,
the negative control pigs challenged with PBS buffer had no viremia or fecal virus shedding
at any time.
DISCUSSION
The current licensed and experimental HEV vaccines are all based on the recombinant
capsid protein derived from a single strain of HEV. The identification of numerous
genetically distinct animal strains of HEV and the demonstrated cross-species infection by
these animal strains raise a question as to whether a vaccine based on a single HEV strain
will confer sufficient protection against strains from different genotypes especially those
animal strains with zoonotic potential. To our knowledge, this is the first study evaluating
the cross-protection efficacy of recombinant capsid antigens derived from various animal
HEV strains as candidate vaccines against HEV challenge in a pig model.
Vaccine trials of HEV ORF2 antigens have been performed in chickens [30], non-human
primates [36, 41], and humans [27, 28]. A recombinant truncated capsid protein expressed in
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baculovirus induced complete protection in rhesus monkeys against both hepatitis and
infection after challenge with genotype 1 or 3 HEV. Monkeys were also completely
protected from hepatitis and partially protected from infection after challenge with a
genotype 2 HEV [42], indicating effective cross-protection among the four recognized
genotypes of mammalian HEV [43]. In a comprehensive human vaccine trial with over
100,000 participants, a bacterially-expressed recombinant HEV ORF2 protein induced
complete protection for at least 1 year [27], and this vaccine has now been approved and
licensed in China. It has also been shown that previous infection with a strain of HEV likely
confers protection against subsequent infections from different strains [44]. We previously
demonstrated that prior infection of pigs with a genotype 3 swine HEV protected pigs
against subsequent infections with genotypes 3 and 4 human HEV and partially protected
against homologous genotype 3 swine HEV re-infection [37].
Since HEV infection in pigs is subclinical, the incidence and duration of viremia and fecal
virus shedding as well as microscopic liver lesions are typically used as parameters to
evaluate protection against infection. In this present study, all 6 unvaccinated pigs had fecal
virus shedding after challenge lasting two consecutive weeks in 50% of the pigs. In contrast,
in avian HEV and swine HEV antigen-vaccinated pigs, only three pigs in each group had
fecal virus shedding with only 1 pig lasting 2 weeks, indicating that the avian HEV and
swine HEV capsid antigens induce certain levels of protection against the genotype 3 HEV
challenge (Table 3). Although the protection was not complete in all pigs, as seen similarly
in non-human primate and chicken HEV capsid vaccine studies, the results from this study
did indicate a cross-protection of the avian HEV capsid antigen against genotype 3
mammalian HEV. Although the avian HEV shares only 50–60% sequence identity with
mammalian HEV strains [2, 3, 17], the avian HEV may be more antigenically related to the
mammalian HEV. In fact, the capsid protein of avian HEV has been shown to share
common antigenic epitopes with the human HEVs [45, 46]. In pigs vaccinated with the rat
HEV capsid antigen, all challenged pigs had fecal virus shedding similar to the unvaccinated
challenged control pigs, suggesting that the rat HEV antigen does not induce sufficient level
of protection against genotype 3 HEV. This is not surprising as the rat HEV is genetically
very divergent from human HEVs, and in fact the rat HEV belongs to a unique new
genotype [21, 22]. It is possible that the rat HEV may not share common neutralizing
epitopes in the capsid with the genotype 3 HEV.
In general, histological hepatic lesions characterized by lymphoplasmacytic inflammation
are mild in pigs infected with swine HEV. At necropsy, the mean score of liver lesions in the
unvaccinated/challenged group was higher than in all three vaccinated/challenged groups,
suggesting a certain level of cross-protection of the three animal HEV antigens against
genotype 3 HEV, which is consistent with the fecal virus shedding data. Interestingly, the
pigs vaccinated with the avian HEV antigen had no detectable histological liver lesions,
further indicating that avian HEV capsid antigen confers cross-protection against genotype 3
mammalian HEV. The inability of propagating HEV in a cell culture system to produce a
higher titer challenge virus stock and the subclinical infection nature of genotype 3 HEV in
pigs limited our ability to conduct a more robust challenge study to fully assess the cross-
protective ability of these animal HEV-derived antigens. We are also limited by the fact that
samples were collected weekly whereas daily samples would probably provide a better
picture regarding the duration of fecal virus shedding. The lack of viremia in even the
unvaccinated/challenged pigs is not unexpected since viremia is often absent or transient in
HEV-infected pigs [12, 37, 40, 47]. Nevertheless the combined histological evaluation and
fecal virus shedding data suggest that the capsid antigens derived from avian, swine and rat
HEV confer at least partial cross-protection against genotype 3 HEV challenge in pigs.
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The results from the Western blot analysis revealed that the truncated capsid antigens
derived from swine, rat, and avian HEV cross-reacted antigenically with anti-HEV
antiserum raised against a genotype 1 human HEV [7]. Similarly, we previously showed that
the rabbit HEV antiserum cross-reacted with swine, human, rat and avian HEV ORF2
protein, and conversely the rabbit HEV ORF2 antigen cross-reacted with genotype 1 human,
genotype 3 swine, avian and rat HEV antisera [12]. Taken together, these results
demonstrated antigenic cross-reactivity among animal strains of HEV but also significant
antigenic variability which may explain the partial cross-protection seen in this study.
In conclusion, vaccination of pigs with recombinant capsid antigens derived from three
animal strains of HEV induced strong IgG anti-HEV antibody response in vaccinated pigs,
which is consistent with other studies that showed a robust seroconversion to IgG anti-HEV
after vaccination with HEV ORF2 antigens [29, 30, 41]. However, the recombinant antigens
from the 3 animal strains of HEV appear to confer only partial cross-protection against a
genotype 3 mammalian HEV. Additional studies are warranted to fully evaluate if the
current experimental vaccines based on a single HEV strain will confer efficient protection
against all known mammalian genotypes of HEV, especially the novel zoonotic animal
strains of HEV. Furthermore, it will be interesting in the future to determine if addition of an
adjuvant will further enhance the protection of the ORF2 antigen-based vaccine.
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Highlights
> Capsid antigens from rat, swine and chicken HEVs cross-reacted with human
HEV
> Capsid antigens derived from animal HEVs induced a strong IgG anti-HEV
response
> Capsid antigens from animal HEVs only partially protect against a genotype
3 HEV
> The results have important implications for the efficacy of current HEV
vaccines
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Figure 1. Western blot analyses of truncated bacterial-expressed recombinant swine, rat, and
avian HEV ORF2 capsid antigens
Each lane was loaded with truncated recombinant capsid proteins derived from swine HEV
(1), rat HEV (2), or avian HEV (3) HEV. Panel A: A PVDF membrane containing the
separated proteins was incubated with IRDye800 conjugated antibody against 6-His residue
tags to detect the respective recombinant fusion capsid proteins. Panel B: A PVDF
membrane containing the separate proteins was first incubated with a anti-HEV ORF2
hyperimmune swine antiserum raised against the genotype 1 human HEV followed by
incubation withIRDye800 conjugated antibody against swine IgG. Both membranes were
read at wavelength 800 nm using an Odyssey Imager (LI-COR biosciences).
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Figure 2. IgG anti-HEV antibody responses in pigs vaccinated with various recombinant HEV
antigens as tested by ELISA
A: PBS buffer; B: swine HEV ORF2 antigen; C: rat HEV ORF2 antigen; D: avian HEV
ORF2 antigen. Pigs were vaccinated on day 0 and a booster dose was given on day 14.
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Table 1
Oligonucleotides used for amplification of truncated ORF2 proteins and for the detection of HEV RNA
Primer ID Sequence (5’--3’) Purpose
SwineORF2-Fa 5’-AAGGATCCATGGCTGTATCACCGGCCCCCGAC-3’ Amplification of swine
SwineORF2-Ra 5’-AACTCGAGTTAAGACTCCCGGGTTTTACC-3’ HEV ORF2 gene
SPK240-Fb 5’-CATCATGGATCCGCACAGGCACCGGC-3’ Amplification of rat
SPK241-Rb 5’-CATCATAGATCTTCAGACACTATCGGCGGC-3’ HEV ORF2 gene
SPK239-Fb 5’-CATCATGGATCCGACGTTGTCACCGCGG-3’ Amplification of avian
SPK238-Rb 5’-CATCATAGATCTTTAGGGTGGTGAGGGGAATG-3’ HEV ORF2 gene
HEVORF1-FWD1 5’-TCGTCTCCTCTACACCTATC-3’ RT-PCR
HEVORF1-REV1 5’-CGATCTCTAACGCTAGGTTG-3’ RT-PCR
HEVORF1-FWD2 5’-CGACTGAGTTCATTATGCGTG-3’ RT-PCR
HEVORF1-REV2 5’-CCTCAGTTATAGTAAGCGCC-3’ RT-PCR
a
Built-in BamHI and XhoI restriction sites underlined to facilitate cloning.
b
Built-in BamHI and BglII restriction sites
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Table 2
Hepatic histological lesion scores at 4 weeks post-challenge in vaccinated and control pigs challenged with a
genotype 3 HEV
Vaccine
group
Pig
ID#
Challenge
inocula
Liver histological
lesion score a
Mean histological liver lesion
Score
PBS 11 PBS 0 0.17
13 1
14 0
16 0
17 0
29 0
Swine HEV 2 Genotype 3 0 0.33
ORF2 10 HEV 0
12 1
15 0
18 0
40 1
Rat HEV 19 Genotype 3 0 0.33
ORF2 20 HEV 0
22 1
24 0
26 0
31 1
Avian HEV 4 Genotype 3 0 0.00*
ORF2 8 HEV 0
21 0
23 0
25 0
32 0
PBS 3 Genotype 3 0 0.67*
5 HEV 1
9 0
30 1
39 1
42 1
a
Lymphoplasmacytic scores: 0 = no inflammation, 1=1 to 2 lymphoplasmacytic infiltrates/10 hepatic lobules, 2 = 3 to 5 focal infiltrates/10 hepatic
lobules, 3 = 6 to 10 focal infiltrates/10 hepatic lobules, and 4 = >10 focal infiltrates/10 hepatic lobules [39].
*
statistical significance (P < .05)
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